1. DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?

4. HCV-Related Cirrhosis Is Projected to Peak Over the Next 10 Years

5. Sustained Virologic Response Improves Overall Survival in Chronic HCV with Advanced Fibrosis

7. DAAs as Components of New Treatment Paradigm for Hepatitis C

9. Eric the Sailor

10. The story continues

11. Interferon has a Dual Mechanism of Action: Viral Inhibition and Immune Modulation

12. The addition of RBV Significantly Accelerates Viral Decay

13. Pharmacokinetics of Once Daily Compared with Twice Daily Regimen of Ribavirin

14. Eric’s HCV Treatment course

15. Definitions of Response

21. DAAs - Key Characteristics

22. Protease Inhibitor DAAs in Clinical Trials

23. 5 Non Nucleoside Polymerase Inhibitors

24. 4 Nucleoside Analogue Polymerase Inhibitors

25. 4 NS5A Inhibitors

26. 3 Other Classes

27. Eric Update

28. Eric comes ashore

29. Rash Decisions

30. Progress on study

32. Eric Week 24 to 48 and 72

33. Newly Approved HCV Agents: Telaprevir and Boceprevir

34. Treatment Naïve HCV G1

35. Sprint 2 Boceprevir Naïve

36. Sprint 2 SVR and Relapse Rates

37. SPRINT-2 and RESPOND-2: HCV G1 Subtype as a Predictor of SVR in Patients with Poor IFN Response (BOC Arms Combined)

38. Patients With Poor Interferon Response and Fail Treatment Are More Likely to Have RAVs

40. Changes in HCV RNA over Time During Previous Phase I Studies (101/103)

41. C219: HCV RNA Values over Time (Week 8 Interim Analysis, TVR-exposed)

42. MK 5172 Second Generation PI

44. Advance: SVR and Relapse Rates

45. Previously Treated Patients HCV G1

46. Respond-2

47. Respond-2

49. REALIZE: Insulin resistance was not an independent determinant of SVR

50. REALIZE: Impact of anemia/RBV dose reduction on SVR

51. PILLAR Study:TMC 435 SVR24 (ITT)

52. Silen C 1 Virologic response BI 1335

53. Atlas Efficacy: Achievement of HCV RNA <15 IU/mL

55. PSI-7977 ELECTRON: Study Design for HCV GT2/3

56. PSI-7977 ELECTRON 100% concordance of SVR12 with SVR24

57. PSI-7977 ELECTRON What is the role of Ribavirin?

58. BI and BI , with and without ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Week 12 interim results of the SOUND-C2 study

59. SVR-12

60. Background

61. BMS-790052 (NS5A inhibitor) + BMS-650032 (PI) ± PR in null responders: phase IIa study

62. Virologic Response before and after treatment

64. Dual therapy with BMS 790052 + BMS 650032 in HCV genotype 1B null responsders

66. The Holy Grail